title: Complications of Tenckhoff catheter implantation in patients with multiple previous intraabdominal procedures for ovarian carcinoma.
abstract: In patients with minimal residual ovarian carcinoma after aggressive surgical and chemotherapeutic treatment, nephrotoxicity and/or peripheral neuropathy often prohibit continued treatment with intravenous combination cisplatin-based chemotherapy. It is attractive to continue treatment of these patients with intraperitoneal (ip) delivered chemotherapy. From 1981 through 1984 a Tenckhoff catheter was implanted in 59 women for ip chemotherapy after a staging laparoscopy or laparotomy. Minor complications occurred in 8 patients and could be treated conservatively. Ten patients suffered major complications, leading to three (re)laparotomies and catheter extraction in 7 of 10 patients. No patient died of complications, but mean hospitalization time of patients with major complications was 25 days as compared to 11 days for patients without complications. An analysis of nine factors that could lead to postoperative complications failed to reveal a statistically significant risk factor. From this study no profile of a typical high-risk patient emerges.
authors.affiliation: Division of Clinical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Amsterdam.
authors.forename: P W
authors.initials: PW
authors.lastname: de Graaf
authors.forename: M M
authors.initials: MM
authors.lastname: Mellema
authors.forename: W W
authors.initials: WW
authors.lastname: ten Bokkel Huinink
authors.forename: E J
authors.initials: EJ
authors.lastname: Aartsen
authors.forename: R
authors.initials: R
authors.lastname: Dubbelman
authors.forename: H R
authors.initials: HR
authors.lastname: Franklin
authors.forename: A A
authors.initials: AA
authors.lastname: Hart
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy* / Q000601:surgery; D002404:Catheterization / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal / Q000295:instrumentation*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents